Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Institute of Neuroscience, Nanchang University, Nanchang, Jiangxi, China.
Cancer Med. 2022 May;11(9):2020-2035. doi: 10.1002/cam4.4603. Epub 2022 Feb 10.
The therapeutic effects of conventional treatment on gliomas are not promising. The tumor microenvironment (TME) has a close association with the invasiveness of multiple types of tumors, including low-grade gliomas (LGG). This study aims to validate the prognostic and immune-related role of macrophage scavenger receptor 1 (MSR1) in LGG patients.
Data in this study were obtained from public databases. The differential expression of MSR1 was analyzed in LGG patients with different clinicopathological characteristics. Kaplan-Meier survival analysis, a time-dependent receiver operating characteristic (ROC) curve, and Cox regression analysis were used to assess the prognostic value of MSR1. Differentially expressed genes (DEGs) were screened between the high and low expression groups of MSR1. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to annotate the function of these DEGs. Hallmark gene sets were identified based on MSR1 by Gene Set Enrichment Analysis (GSEA). Difference analysis and correlation analysis were used to study the relationship between MSR1 and TME-related scores, tumor-infiltrating immune cells (TIICs), immune-related gene sets, and immune checkpoints (ICPs). The single-cell sequencing data were processed to identify the cell types expressing MSR1. The quantification of TIICs in TME was calculated by single-sample gene set enrichment analysis (ssGSEA). The differential expression of MSR1 in LGG and control brain tissues was verified by experiments.
There were significant differences in the expression level of MSR1 in different types of tissues and cells. MSR1 has a high prognostic value in LGG patients and can be used as an independent prognostic factor. MSR1 is closely related to TME and may play an important role in the immunotherapy of LGG patients.
The result of our study demonstrated that MSR1 is an independent prognostic biomarker in LGG patients and may play an important role in the TME of LGGs.
传统治疗方法对神经胶质瘤的疗效并不理想。肿瘤微环境（TME）与多种肿瘤的侵袭性密切相关，包括低级别胶质瘤（LGG）。本研究旨在验证巨噬细胞清道夫受体 1（MSR1）在 LGG 患者中的预后和免疫相关作用。
本研究数据来自公共数据库。分析不同临床病理特征的 LGG 患者中 MSR1 的差异表达。Kaplan-Meier 生存分析、时间依赖性接受者操作特征（ROC）曲线和 Cox 回归分析用于评估 MSR1 的预后价值。筛选 MSR1 高低表达组之间的差异表达基因（DEGs）。GO 和 KEGG 用于注释这些 DEGs 的功能。基于 MSR1 通过基因集富集分析（GSEA）确定标志性基因集。差异分析和相关性分析用于研究 MSR1 与 TME 相关评分、肿瘤浸润免疫细胞（TIICs）、免疫相关基因集和免疫检查点（ICPs）之间的关系。对单细胞测序数据进行处理以识别表达 MSR1 的细胞类型。通过单样本基因集富集分析（ssGSEA）计算 TME 中 TIICs 的定量。通过实验验证 MSR1 在 LGG 和对照脑组织中的差异表达。
MSR1 在不同类型的组织和细胞中的表达水平存在显著差异。MSR1 在 LGG 患者中具有较高的预后价值，可以作为独立的预后因素。MSR1 与 TME 密切相关，可能在 LGG 患者的免疫治疗中发挥重要作用。
我们的研究结果表明，MSR1 是 LGG 患者独立的预后生物标志物，可能在 LGG 的 TME 中发挥重要作用。
